Suchergebnisse - "Cairns, David A"

PubPharm (127)

1

Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma : results from the NCRI Myeloma X (intensive) trial

enthalten in: Bone marrow transplantation | 2024

von de Tute, R. | Cook, G. | Cairns, D. | +12

2

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

enthalten in: The New England journal of medicine | 2024

von Munir, T. | Cairns, D. | Bloor, A. | +121

3

Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases : EPA for Metastasis Trial 2 (EMT2) study protocol

enthalten in: BMJ open | 2023

von Hull, M. | Ow, P. | Ruddock, S. | +16

4

How is overall survival assessed in randomised clinical trials in cancer and are subsequent treatment lines considered? A systematic review

enthalten in: Trials | 2023

von Royle, K. | Meads, D. | Visser-Rogers, J. | +2

5

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial

enthalten in: EClinicalMedicine | 2023

von Jones, J. | Cairns, D. | Menzies, T. | +15

6

NET-02 : a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma

enthalten in: EClinicalMedicine | 2023

von McNamara, M. | Swain, J. | Craig, Z. | +21

7

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR) : interim analysis of a multicentre, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2023

von Hillmen, P. | Pitchford, A. | Bloor, A. | +29

8

The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages : results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial

enthalten in: British journal of haematology | 2023

von Jenner, M. | Pawlyn, C. | Davies, F. | +16

9

Optimizing the value of lenalidomide maintenance by extended genetic profiling : an analysis of 556 patients in the Myeloma XI trial

enthalten in: Blood | 2023

von Panopoulou, A. | Cairns, D. | Holroyd, A. | +13

CommentIn: Blood. 2023 Apr 6;141(14):1649-1650. - PMID 37022733

10

Personalizing neoadjuvant chemotherapy for locally advanced colon cancer : protocols for the international phase III FOxTROT2 and FOxTROT3 randomized controlled trials

enthalten in: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland | 2023

von Platt, J. | Williams, C. | Craig, Z. | +4

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[13]